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Abstract 
Diabetes mellitus (DM) is a public health issue, affecting around 382 million people worldwide. In order to achieve gly-
cemic goals, insulin therapy is the frontline therapy for type 1 DM patients; for patients with type 2 DM, use of insulin 
therapy is an option as initial or add-on therapy for those not achieving glycemic control. Despite insulin therapy 
developments seen in the last decades, several barriers remain for insulin initiation and optimal maintenance in clini-
cal practice. Fear of hypoglycemia, weight gain, pain associated with blood testing and injection-related pain are the 
most cited reasons for not starting insulin therapy. However, new generation of basal insulin formulations, with longer 
length of action, have shown the capability of providing adequate glycemic control with lower risk of hypoglycemia.
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Insulin therapy development
Diabetes mellitus (DM) affects around 382 million people 
worldwide, with type 2 DM accounting for 85–95  % of 
all cases [1]. Diabetes may be managed with tight glyce-
mic control, aiming to achieve glycosylated hemoglobin 
(A1C) levels below or around 7 %, considering even more 
stringent goals (such as <6.5 %) for selected patients. This 
can be achieved without significant adverse events, as 
hypoglycemia [2], due to the relation of lower A1C lev-
els with fewer microvascular complications [3–6]. Insulin 
therapy is recommended as frontline therapy for type 1 
DM patients; for patients with type 2 DM, use of insu-
lin is an option as initial or add-on therapy for those 
not achieving glycemic control with initial oral drugs 
[2]. Currently, only in the United States, around 6 mil-
lion people aged ≥18 years with DM use insulin therapy 
(28.7 % of the DM patients population in this age in the 
country) [7].
Insulin was first used in diabetic patients in the 1920s 
[8], but the first commercial preparations contained 
numerous impurities and relevant potency variation 
[9]. In the 1930s protamine zinc insulin was developed, 
resulting in delayed absorption and longer duration of 
action, thus reducing the number of doses needed for 
insulin replacement—but still with considerable insta-
bility [10]. In 1946, neutral protamine Hagedorn (NPH) 
insulin was produced and could be pre-mixed with solu-
ble insulin, becoming the main basal insulin throughout 
the 20th century [10].
In the early 1980s, the development of human insulin 
innovated with refinement of insulin therapy, especially 
regarding basal insulin [9]. New long-acting insulin ana-
logues, glargine and detemir, showed less day-to-day 
variability and longer duration of action, thus allowing 
once-daily dosing [11, 12].
The search for an ideal insulin therapy regimen still 
continues, aiming to provide optimal glycemic control 
with limited adverse events and improved convenience to 
the patient [13] (Fig. 1).
Pharmacokinetic and pharmacodynamics profiles 
of insulin therapy
Overall development of insulin aims to decrease patients’ 
hypoglycemia episodes and improve pharmacokinetics 
(PK)/pharmacodynamics (PD) profile, by mimicking as 
close as possible the normal insulin release [14]. Vari-
ability of PK profile among insulins directly influences 
PD effects, increasing the probability of hypoglycemia 
episodes due to unpredictability of insulin peaks. In addi-
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is affected by several factors, thus PK and PD profiles of 
insulin may be studied separately, each with its specific 
measurement [15, 16].
In order to minimize hypoglycemia or hyperglycemia 
episodes, insulin analogues with different PK/PD pro-
files were developed, including basal and ultra-long basal 
insulins. Unfortunately, current insulin options do not 
fulfill the main requirements for ideal basal insulin: flat 
PD profile, with low hypoglycemia risk, 24  h duration, 
and low interindividual variability (Fig. 2).
Insulin NPH has a delayed absorption profile, with 
a peak in 4.5  h after administration. Besides, insulin 
NPH action doesn’t last for 24 h, so usually it has to be 
administered at least twice a day. Furthermore, NPH 
treatment has high inter and intraindividual variability 
[17]. Thus, other insulins were developed to improve 
PK/PD profile.
In 2000, insulin glargine was the first long-acting insu-
lin analogue available. After subcutaneous injection, 
glargine precipitates in the subcutaneous tissue delaying 
the absorption [18]. Insulin glargine has one amino acid 
substituted in the A chain and two in the B chain: this 
modifies the isoelectric point of the protein, decreasing 
its solubility at physiologic pH. Due to its delayed absorp-
tion, glargine also demonstrates a flatter PK/PD profile, 
with longer duration and less variability when compared 
to NPH [17].
Insulin detemir is another bioengineered insulin devel-
oped by removing a threonine and acylating a lysine resi-
due with 14-carbon fatty acid, both in the B chain. It has 
a PK/PD profile very similar to glargine (flatter PK/PD 
profile, approximately 24-h duration and low variability), 
although insulin glargine is slightly more effective and 
stable in glycemic control [19].
However, both glargine and detemir still do not com-
pletely mimic physiological insulin secretion. When 
administered in high doses, both show a peak on PK/
PD profile [20]; also, a low dose may not be enough to 
cover a 24-h period and there is still interindividual vari-
ability [21]. To attempt to overcome this issue, ultra-long 
insulins were developed, being degludec, LY2605541 and 
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Fig. 1 Timeline for insulin developments. Adapted from Owens [10]
Fig. 2 Comparison between the action time profiles of different 
insulins. Adapted from: Tibaldi [59]
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Insulin degludec is a modified B chain analogue that, 
like other insulin, forms hexamers and di-hexamers 
when injected subcutaneously. As the slow diffusion of 
zinc molecule, present in the hexamer, occurs, the insu-
lin monomer is finally absorbed. Compared with insu-
lin glargine and detemir, degludec promotes flatter PK/
PD profiles, decreasing the number of confirmed hypo-
glycemia episodes [22]. Insulin degludec has a half-life 
superior to 25 h, with action exceeding 42 h, however the 
most studied schedule in clinical trials is based on once 
daily doses.
Insulin LY2605541 (or PEGylated Lispro) has polyethyl-
ene glycol (PEG) polymer chain attached in the molecule 
structure. PEGylation slows LY2605541 subcutaneous 
absorption and decrease its renal clearance, promoting 
the creation of a peakless PK/PD profile and increasing 
LY2605541 half-life. LY2605541 presents a PK/PD profile 
very similar to insulin degludec, with mean half-life of 
35 h [23, 24] but, differently from degludec, LY2605541 
causes weight loss and hepatic lipid accumulation in 
both type 1 [25] and type 2 DM [24]. The mechanisms of 
hepatic lipid accumulation are unknown but led to the 
discontinuation of this insulin.
The most recent clinical approach for ultra-long insu-
lin is glargine U300 (300  U/ml). The analogue has the 
same mechanism to extent absorption as insulin glar-
gine. When administered subcutaneously, U300 forms 
subcutaneous depot with smaller surface area, creating a 
prolonged release that results in a flatter PK/PD profile 
than in glargine U100. Furthermore, exposure to U300 is 
more evenly distributed (Fig. 3) [26], and glucose control 
remains for 36 h [27], resulting in decreased hypoglyce-
mic episodes (overall and nocturnal) in insulin-based [28] 
or insulin combined with oral antihyperglycemic drugs 
therapy [29]. U300 also demonstrated reduced variability 
and a tendency to decrease weight gain compared with 
glargine U100.
It should be highlighted that insulin therapy should 
always try to mimic the physiological insulin release, thus 
longer half-life insulin is not always the best choice. As an 
example, ultralente insulin has a mean duration of 20 h, 
which is superior to 14 h of insulin NPH [17]. However, 
this insulin presents higher interindividual variability, 
higher incidence of hypoglycemia episodes and worse 
glucose control when compared with NPH [17, 26]. Due 
to its inferior clinical profile, ultralente was withdrawn 
from the market in 2005.
Ultra-long insulins offer efficacy and safety, with less 
pharmacodynamics variability and intraindividual vari-
ability, and duration of action over 24  h. Among these 
insulins, both U300 and degludec can be used as basal 
and basal-bolus therapy, in type 1 and type 2 DM, offer-
ing the advantage of flexibility. This means that health-
care professionals and diabetic patients don’t need to be 
rigid about the timing of injections.
Clinical trials evaluating ultra‑long‑acting insulin 
formulations
Insulin degludec for type 1 DM
BEGIN was an open-label, treat-to-target, non-inferior-
ity, multicentric trial assessing adult patients with type 
1 DM who had been treated with basal-bolus insulin 
for at least 1  year (70  % receiving insulin glargine and 
19  % receiving insulin detemir at screening) [23]. In 
total, 626 participants were randomized in a 3:1 ratio to 
receive once-daily insulin degludec (100  U/mL; 3  mL) 
or insulin glargine (100 U/mL; 3 mL), both in combina-
tion with mealtime insulin aspart. Primary objective was 
Fig. 3 Concentration of insulin glargine U300 versus U100 over time in steady. Adapted from Becker et al. [26]
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to confirm non-inferiority of degludec over glargine in 
reducing A1C levels after 52  weeks of treatment [23]. 
Insulin degludec demonstrated to be non-inferior, with 
a reduction in A1C levels by 0.4 % points versus 0.39 % 
points with glargine (difference of −0.01 % points; 95 % 
CI −0.14–0.11; p  <  0.0001 for non-inferiority). Rates of 
overall confirmed hypoglycemia were similar in both 
groups, but the rate of confirmed nocturnal hypogly-
cemia was 25  % lower with degludec (4.41 versus 5.86 
episodes/patient-year of exposure; relative risk 0.75; CI 
95 % 0.59–0.96). No differences in weight gain or in other 
adverse events were observed between study groups [23]. 
A 52-week extension of the BEGIN trial corroborated the 
benefits of degludec on confirmed nocturnal hypoglyce-
mia, with a sustained event reduction of 25 % (CI 95 % 
from 5 to 41 %), without significant differences in efficacy 
or in other adverse events [30]. These data evidence the 
efficacy and safety of degludec, as well as its non-inferior-
ity in relation to insulin glargine.
A subsequent trial (BEGIN: Flex T1) investigated effi-
cacy and safety of insulin degludec once daily, but varying 
the injection time [31]. This was an open-label, treat-to-
target, non-inferiority trial comparing insulin degludec 
(100 U/mL) in a fixed schedule (with minimum 8 h and 
maximum 40  h between doses) with degludec (100  U/
mL; 3  mL) or glargine (100  U/mL; 3  mL) given at the 
same time every day, once daily, with mealtime insulin 
aspart. After 26 weeks of treatment, mean A1C and fast-
ing plasma glucose levels were reduced similarly in the 3 
groups. Insulin degludec in the flexible schedule achieved 
non-inferiority and significantly reduced confirmed noc-
turnal hypoglycemia [31]. Also, the study highlighted the 
advantage of the long duration of degludec in offering 
more flexibility in terms of injection timings.
Insulin degludec for type 2 DM
BEGIN basal-bolus type 2 study was an open-label treat-
to-target, non-inferiority trial, performed at 123 sites in 
12 countries. The study enrolled adult patients with type 
2 DM who had been treated with any insulin regimen for 
at least 3 months with or without oral antidiabetic drugs 
and had A1C concentrations of 7.0–10.0  % [32]. This 
trial randomized 1006 patients (3:1) to receive once-daily 
insulin degludec (100  U/mL; 3  mL) or glargine (100  U/
mL; 3 mL), in combination with mealtime insulin aspart, 
with or without prescribed metformin, pioglitazone or 
both. The primary objective was to confirm the non-
inferiority of degludec over glargine in reducing A1C lev-
els. After 1 year, A1C decreased by 1.1 % in the degludec 
group and 1.2 % in the glargine group (estimated differ-
ence degludec-glargine: 0.08  %; 95  % CI −0.05 to 0.21), 
confirming its non-inferiority [32]. Rates of overall con-
firmed hypoglycemia were lower with degludec (11.2 
versus 13.6 episodes/patient-year of exposure; estimated 
ratio 0.82; 95  % CI 0.69–0.99), as well as rates of con-
firmed nocturnal hypoglycemia (1.4 versus 1.8 episodes/
patient-year of exposure; estimated ratio 0.75; 95  % CI 
0.58–0.99). Rates of severe hypoglycemia were too low 
to assess differences, and adverse events occurred in 
a similar rate in both groups [32]. A 26-week extension 
showed that degludec maintained similar improvement 
in glycemic control compared with glargine, with fewer 
hypoglycemic episodes (24 % overall reduction and 31 % 
confirmed nocturnal episodes reduction) [33].
Another 1-year large phase 3 trial (BEGIN Once 
Long) randomized 1030 patients (3:1) with type 2 DM, 
insulin-naïve, inadequately controlled with oral anti-
diabetic drugs (A1C 7–10 %) to receive insulin degludec 
or glargine once daily, both combined with metformin 
[34]. Insulin degludec showed similar rates of glycemic 
control but, again, with reduced risk of confirmed noc-
turnal hypoglycemia as well as of severe adverse events 
[34]. The 52-week extension of BEGIN Once Long trial 
showed sustained benefits of insulin degludec in hypo-
glycemic episodes [35].
Flexible schedule of administration of insulin degludec 
has also been studied in type 2 DM patients. BEGIN Flex 
trial assessed 687 patients (41.8 % already receiving insu-
lin therapy) randomized to receive degludec in a flexible 
once-daily schedule (with prespecified rotating doses of 
8–40 h intervals), degludec once daily at the main even-
ing meal, or glargine [36]. In this trial, no differences 
between groups were reported on glycemic control, 
hypoglycemia or adverse events, suggesting that daily 
injection time of insulin degludec can vary without com-
promising efficacy [36].
Insulin glargine 300 units/mL for type 1 DM
EDITION 4 trial is a randomized, phase 3a, open-label 
study recently published (2015). The study randomized 
549 patients (1:1:1:1) to receive once-daily insulin glar-
gine 300U or 100U, in the morning or evening, while 
continuing mealtime insulin. Participants had diabetes 
duration of 21 years and HbA1c level of 8.1 % [37]. Over-
all, glargine 300U was non-inferior over glargine 100U 
for the primary endpoint (HbA1c change from baseline), 
with reductions of 0.40 versus 0.44 %, respectively (mean 
difference 0.04; CI 95  % −0.10 to 0.19  %). Event rates 
of confirmed or severe hypoglycemia (≤3.9  mmol/L) 
were similar in both groups while nocturnal hypoglyce-
mia was lower in glargine 300U group during the first 
8  weeks of the study [37]. Insulins or times of injection 
showed no differences in glycemic control, hypoglycemia 
or adverse events between groups. Glargine 300U led to 
a statistically significant lower weight gain (mean differ-
ence −0.56  kg; CI 95  % −1.09 to −0.03  kg) [37]. Also, 
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the convenience of a once-daily injection and lower rates 
of hypoglycemia should convert into improvements in 
treatment satisfaction.
Insulin glargine 300 units/mL for type 2 DM
EDITION 1 was a 6-month multinational (conducted in 
13 countries), open-label trial that assessed adult patients 
with type 2 DM who were receiving basal-bolus insulin 
therapy (requiring ≥42 units/day of basal insulin) for at 
least one year (57.4 % with prior use of metformin; other 
oral antidiabetic therapies were not allowed) and with 
A1C levels 7.0–10.0 %. Participants (n = 807) were ran-
domized to receive once-daily injections of insulin glar-
gine 300U or 100U through 6 months [28]. Reduction in 
A1C levels (primary endpoint) was similar in both groups 
(mean change of −0.83 % for both groups), meeting the 
non-inferiority criterion. The main secondary endpoint 
was the percentage of patients with one or more con-
firmed or severe nocturnal hypoglycemia (≤3.9 mmol/L) 
reported between week 9 and month 6 and patients 
receiving glargine 300U achieved better results, with a 
21 % risk reduction (relative risk 0.79; 95 % CI 0.67–0.93). 
Adverse events or treatment-emergent adverse events 
were equally distributed between the groups [28]. A pre-
planned 6-month extension showed sustained glycemic 
control and less hypoglycemia with glargine 300U [38]. 
A lower percentage of participants receiving insulin glar-
gine 300U experienced confirmed or severe hypoglyce-
mia (85.9 versus 91.5 %; RR =  0.94; CI 95 % 0.89–0.97) 
and the annualized rate of documented symptomatic 
nocturnal hypoglycemia was lower in this group (1.8 
versus 2.5 per participant-year; RR = 0.74; CI 95 % 0.56–
0.97) [38].
EDITION 2 was a randomized phase 3 trial with a 
design similar to EDITION 1: it was a 6-month, open-
label trial conducted in 213 centers across 13 coun-
tries, analyzing adult patients with type 2 DM who were 
receiving basal insulin therapy (requiring ≥42 units/day 
of basal insulin) for at least 1  year and with A1C levels 
7.0–10.0  % [29]. This study differed from EDITION 1 
because patients were not receiving mealtime rapid-act-
ing insulin and they could receive other antidiabetic ther-
apies, except sulphonylureas and glinides (in 94  %, oral 
therapy was metformin). Participants (n = 811) were ran-
domized to receive once-daily injections of insulin glar-
gine 300U or 100U in the study period. Primary endpoint 
was change in A1C levels from baseline to month 6 and 
the results were statistically similar in both groups (mean 
change of −0.57  % for glargine 300U and −0.56  % for 
glargine 100U), meeting the non-inferiority criterion. The 
main secondary endpoint was the percentage of patients 
with one or more confirmed or severe nocturnal hypo-
glycemia event (≤3.9 mmol/L) reported between week 9 
and month 6 and it was lower in patients receiving glar-
gine 300U (21.6  %) than glargine 100U (27.9  %), with a 
risk reduction of 23 % (relative risk of 0.77; 95 % CI 0.61–
0.99). EDITION 2 participants continued in a 6-month 
safety extension in order to examine long-term outcomes 
[39]. Over 12  months, improved control of HbA1c was 
maintained in both treatment groups, and event rates/
participant-year of confirmed or severe nocturnal hypo-
glycemia were 37  % lower with insulin glargine 300U 
(1.74 versus 2.77; RR = 0.63; CI 95 % 0.42–0.96) [39].
EDITION 3 is another multicentric randomized trial 
evaluating insulin glargine 300U, but assessing insu-
lin-naive adult patients with type 2 DM on oral glu-
cose-lowering drugs [40]. Participants (n  =  878) were 
randomized to receive once-daily injections of insulin 
glargine 300U or 100U, throughout the 6-month study 
period, after discontinuing sulphonylureas and glinides. 
The primary endpoint was change in A1C levels from 
baseline to month 6 and the results showed an equiva-
lent reduction in both groups (mean change of −1.42 % 
for glargine 300U and −1.46 % for glargine 100U; mean 
difference 0.04 %; CI 95 % −0.09 to 0.17 %), meeting the 
non-inferiority criterion. In this trial, non-inferiority was 
pre-defined as a difference <0.4 % in A1C levels between 
the treatment groups. The main secondary endpoint was 
the percentage of patients with one or more confirmed 
or severe nocturnal hypoglycemia event (≤3.9  mmol/L) 
reported between week 9 and month 6 and it was statis-
tically similar in patients receiving glargine 300U (16 %) 
or glargine 100U (17  %). When considering the whole 
6-month treatment period, fewer patients receiving 
glargine 300U experienced such events (18 versus 24 %; 
RR = 0.76; CI 95 % 0.59–0.99) [40].
Flexible dosing intervals of insulin glargine 300U were 
also tested in type 2 DM patients. Patients participat-
ing in EDITION 1 (n =  109) and EDITION 2 (n =  89) 
using glargine 300U were randomized, at month 6, to 
continue the fixed regimen or move to flexible regimen, 
allowing between-injection intervals of 24  ±  3  h on at 
least 2 days each week [41]. In the latter group, through-
out this 3-month flexibility sub-study, only 50–60  % of 
injections ranged 24 ±  1  h. HbA1c change was compa-
rable in fixed versus flexible regimens and hypoglycemia 
events occurred equally between both groups, showing 
that glargine 300U provides flexibility to occasionally 
adapt the timing of insulin injections to individuals’ daily 
changing lifestyle patterns [41].
Barriers for insulin therapy implementation 
and unmet needs: emphasis in hypoglycemia
Several barriers remain for insulin initiation and opti-
mal maintenance in clinical practice, both at the patient 
and at the physician levels. Fear of hypoglycemia, weight 
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gain, pain associated with blood testing and injection-
related pain are the most cited reasons for not starting 
insulin therapy in type 2 DM patients [42]. Also, patient 
perception that insulin therapy is complicated and time 
consuming can interfere with its timely initiation [43]. 
Adherence to insulin therapy, however, is more influ-
enced by factors like health insurance patterns and being 
too busy [44, 45].
Fear of hypoglycemia impacts not only in the decision 
to start insulin therapy, but it may also jeopardize the 
adequacy of glycemic control. It has been reported that 
most physicians would treat patients without adequate 
glucose control in a more aggressively manner if not for 
concerns about hypoglycemia [45].
Burden of hypoglycemia in patients with dm 
receiving insulin therapy
Hypoglycemia is an important adverse event of DM ther-
apy as it potentially impairs the patients’ health-related 
quality of life while imposing other burdens [17, 18]. 
Observational studies report that hypoglycemia occurs 
in up to 42.89 events/patient-year, in type 1 DM patients, 
and in up to 16.36 events/patient-year in insulin-treated 
type 2 DM patients [46, 47]. Rates of severe hypoglycemia 
are approximately of 1.15  events/patient-year, and can 
reach 3.2  events/patient-year in type 1 DM patients; in 
insulin-treated type 2 DM patients, rates are 0.7 events/
patient-year [46, 47].
Nocturnal hypoglycemia, which occurs during sleep, is 
particularly dangerous since patients are unlikely to rec-
ognize symptoms or awake during an episode [48]. In the 
Diabetes Control and Complications Trial (DCCT), 43 
and 55  % of all hypoglycemic and severe hypoglycemic 
events reported, respectively, occurred during sleep [49].
A large web survey conducted in the US with 7.239 
participants with type 2 DM (28.7 % treated with insulin) 
showed that hypoglycemia interfered with social activities, 
causing more absenteeism and decreasing overall work 
productivity, also impacting negatively on overall health-
related quality of life [50]. Another survey, performed in 
US and Europe, attested that even non-severe hypoglyce-
mic events cause major impairments on productivity, with 
productivity loss estimated from U$ 15.26 to U$ 93.47, 
representing 8.3 to 15.9  h of lost work time per month 
[51]. Also, a time trade-off utility study with DM patients 
receiving insulin therapy in US and Canada showed that 
non-severe hypoglycemic episodes led to deterioration 
in utility [52]. Further research has reported that patients 
with confirmed hypoglycemia episodes had significant 
impairment in health-related quality of life [53], greater 
mood disturbance and less work satisfaction [54].
Specific burden of nocturnal hypoglycemia has also 
been studied. A survey recruited DM patients in US, 
Canada and in 7 European countries who experienced 
a non-severe nocturnal hypoglycemia event in the pre-
vious month [55]. The 2108 respondents (32.8  % with 
type 1 and 67.2 % with type 2 DM; 74.2 % receiving insu-
lin therapy) reported that hypoglycemic episodes sig-
nificantly affected sleep and next day functioning, with 
60.7 % stating a moderate to severe impact [55]. Another 
survey assessing 8286 patients in 5 countries (US, Can-
ada, Germany, Sweden and United Kingdom) presented 
that living in a health state with nocturnal hypoglycemia 
is considered worse than living with daytime hypogly-
cemia [56]. Other studies also reported the detrimen-
tal impact of nocturnal hypoglycemia on quality of life, 
including impact on family members and cost-related 
factors [57].
The potential association of hypoglycemia with neu-
rological impairment is also worrisome. A longitudinal 
study following 16,667 older patients with type 2 DM 
(mean age: 65  years; 35  % receiving insulin therapy) 
through 27  years showed an increased risk in dementia 
among patients with reported hypoglycemic episodes, 
with risks growing as the number of episodes increased 
[58].
Additionally, hypoglycemic episodes can lead patients 
to exhibit medication-avoidance behavior, with many 
reducing or even omitting insulin doses after an event, 
which may jeopardize glycemic control [51, 55, 57].
Conclusion
Patients with DM benefit from a tight glycemic control 
strategy, which requires insulin therapy for type 1 DM as 
well as for many patients with type 2 DM. Achieving ade-
quate target levels of blood glucose, however, may lead 
to higher incidence of hypoglycemic episodes, including 
nocturnal events, which are associated with impairment 
in productivity and in health-related quality of life, and 
may also jeopardize cognition in older patients. Further-
more, hypoglycemia is considered a barrier for imple-
menting more intensive therapies, which can reduce the 
chances of attaining optimal glucose control.
New generation of basal insulin formulations, with 
longer length of action, showed the capability of pro-
viding adequate glycemic control, in the same extent as 
insulin glargine, but with decreased risk of hypoglycemia, 
especially nocturnal episodes. Thus, they help fulfilling 
the need to adequate glycemic control with lower risks of 
hypoglycemic events.
The scientific grounds regarding ultra-long basal insu-
lins provide possibilities of its adoption either as upfront 
therapy as well as, in scenarios with cost constraints, for 
patients already receiving long-acting insulins glargine or 
detemir but that have suffered from recurrent episodes of 
hypoglycemia.
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